Palvella Therapeutics Inc.

Contributing Author

Recent Articles by Palvella Therapeutics Inc.

Jun-30	Palvella Therapeutics Added to Russell 3000 and Russell 2000 Indexes PVLA GlobeNewswire
Jun-23	Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% PVLA GlobeNewswire
Jun-18	Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors PVLA GlobeNewswire
Jun-09	Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations PVLA GlobeNewswire
May-27	Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer PVLA GlobeNewswire
May-15	Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
May-08	Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 PVLA GlobeNewswire
May-05	Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 PVLA GlobeNewswire